Selank
Neuroactive anxiolytic peptide; Human evidence mostly regional/limited
Brief Overview: Selank is a synthetic analog related to tuftsin and is discussed for anxiety, stress resilience, and cognition. It is commonly used intranasally in community settings. Evidence lens: There is regional clinical use and mechanistic literature, but broad claims about anxiety disorders, cognition, or withdrawal support should remain carefully qualified. How to read this: if you're new, distinguish acute subjective calm from proven treatment of an anxiety disorder. Once you're past the basics, evaluate route, formulation, nasal tolerability, and interactions with other neuroactive drugs.
- Selank is a synthetic heptapeptide developed from the immunomodulatory peptide tuftsin.
- It is commonly grouped as an anxiolytic/nootropic peptide.
- Selank is a tuftsin-derived anxiolytic/nootropic peptide used mainly intranasally in regional/community contexts. It is distinct from Semax because its intended profile is more anxiolytic than activating.
- Proposed mechanisms include modulation of enkephalinase activity, GABAergic tone, serotonergic signaling, immune-cytokine effects, and stress-response gene expression.
- These mechanisms are not equivalent to a single approved-drug pathway.
- Mechanisms discussed include GABAergic modulation, monoamine effects, immune-neuropeptide signaling, and stress-response gene expression. It does not deliver immediate, benzodiazepine-like anxiolysis. The mechanism here is a plausibility map, not proof of a clinical outcome.
- The evidence base includes Russian clinical and mechanistic work plus community experience.
- It is stronger than pure forum lore but weaker than large multicenter FDA-style trials for anxiety disorders.
- Regional human and preclinical literature exists, but Western regulatory-grade evidence is limited. Community reports are useful context but not definitive efficacy proof. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: Clinical/Trial Protocols [Clinical/Human Trial]; Route: Intranasal; Dose: 0.1% Solution: 2–3 drops per nostril; Daily Dose Total: 400 mcg – 1,200 mcg; Frequency: 2 to 3 times daily; Timing: During acute anxiety / chronically; Duration: 14 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: Common Biohacker Protocols [Community/Biohacker/Anecdotal]; Route: Intranasal; Dose: 250 mcg – 500 mcg (per dose); Daily Dose Total: 500 mcg – 1,000 mcg; Frequency: 1 to 2 times daily; Timing: Morning or before stress events; Duration: 2 to 4 weeks (or as needed); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 3: Subcutaneous researcher note [Research/Experimental]; Route: Subcutaneous (SC); Dose: 100 mcg - 300 mcg; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Intranasal is the dominant route in community and regional use. Dose-per-spray, concentration, nasal technique, and preservative tolerance matter. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: not calculable.
- Half-life basis: reliable modern human PK by common intranasal and injectable products is not established. Reported effects may last longer than measurable plasma exposure.
- Beginner translation: Selank is better thought of as a short-acting neuroactive signal with uncertain exposure, not a drug with a validated accumulation schedule.
- Practical interpretation: Track anxiety scales, sleep, mood, nasal irritation, and interactions with other neuroactive substances.
- Intranasal exposure depends heavily on formulation and technique. CNS effects cannot be assumed from simple nasal administration, and degradation may be rapid. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- Selank is often paired conceptually with Semax: Semax for drive/focus and Selank for calm.
- Combining with benzodiazepines, alcohol, phenibut, SSRIs, stimulants, or other psychoactive agents requires caution and clinician input.
- Often paired with Semax, magnesium, anxiolytic supplements, or sleep protocols. Combining with sedatives or many CNS agents can obscure whether anxiety truly improved. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Potential side effects include nasal irritation, altered taste, headache, fatigue, mood changes, or sleep disruption.
- Bipolar disorder, seizure disorders, pregnancy, breastfeeding, or complex psychiatric medication regimens require clinician review.
- Possible issues include nasal irritation, headache, sedation or paradoxical activation, and mood changes. Long-term use data remain limited. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- Use GAD-7 or similar anxiety scales, sleep tracking, mood logs, HRV if helpful, nasal tolerability, and adverse-event tracking.
- Do not use subjective calm as the only safety marker.
- Track anxiety scales, panic frequency, sleep, daytime sedation, irritability, nasal symptoms, and use of rescue anxiolytics. Objective symptom logs are more useful than single-day impressions. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA: among the 12 peptides HHS removed from Category 2 on April 15, 2026. A specific PCAC review date is not yet set, and compounding-pharmacy access remains blocked pending final FDA action.
- Russia: approved since the late 1990s as an anxiolytic (Registry No. R N002514/01, IBP RAS); No new status change.
- WADA: not currently prohibited.
- Selank is not FDA-approved. Regional availability is distinct from U.S. approval or compounding acceptance. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.